Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — FY2013 Earnings Presentation
21 slides from Vita Life Sciences's earnings presentation, Feb 17, 2014
Slide 1: Results Presentation Year ended 31 December 2013
Vita Life Sciences Ltd ASX: VSC Results Presentation Year ended 31December 2013 herbsofgold’ vitasciends Vital.ife j Enriching Lives . Since 1947 Dedicated to your health \ /| 17 February 2014
Slide 2: Pharmaceutical and healthcare Over-The-Counter business
Pharmaceutical and healthcare Over-The-Counter business Wide range of supplements, vitamins, minerals, meal replacement, sports nutrition and herbal care products Branded under: “Herbs of Gold” and “VitaScience” in Australia “VitaHealth” VitaHealth throughout Asia including Malaysia “Vit
Slide 3: Continued sales growth of 17.3% driven by Asian operations
Continued sales growth of 17 3% driven by Asian 17.3% operations Sales revenue from Asia now accounts for 60% of revenue New Business Units: Thailand, Chi China, Vi Vietnam, t IIndonesia d i and MLM (Malaysia) increased revenue contribution to 15% EBIT $5.51m up 92.7% Strong cash flow: 94.
Slide 4: Year ended 31 December
Year ended 31 December 2013 2012 % Change A $'m A $'m Revenue 35.41 30.19 17.3% EBITDA 5.62 2.93 91.8% EBIT 5.51 2.86 92.7% Profit Before Tax 5.52 2.84 94.4% Profit After Tax 4 75 4.75 2 32 2.32 104 7% 104.7% EPS (Diluted - cents/share) 8.42 4.14 103.4% Dividend (cents/share) 3.00 1.00 200% 3
Slide 5: Revenue A$'m
Revenue‐A$'m Group sales revenue grew by 1717.3% 3% 40.00 against that reported to December 35.00 2012. 30.00 Individual Business Units sales growth: 25.00 Australia 4.7% (2012: 20.1%) 20 00 20.00 Malaysia OTC* 25.1% 15.00 (2012: 18.5%) 10.00 Singapore Si 27.5% 27 5% (2012 (2012: 14 14.0%)
Slide 6: Sales mix by business unit, 2010 vs 2013
FY 2013 NBU 14.7% Australia Total T t l Group G sales l increased i d ffrom $21 $21.0m 0 tto 40.2% Singapore 16.0% $35.4m over 3 years (CAGR: 19.0%) Asian sales (ex Australia) contributed almost 60% of Group revenue in 2013 (2010: 54.7%) New Business Units are Asian based and Malaysia OTC posi
Slide 7: 2013 EBIT Margin
6.0 18.0% 16.0% 5.0 14.0% 40 4.0 12 0% 12.0% EBIT (A$'m) 10.0% 2013 EBIT Margin 3.0 EBIT 8.0% Margin sustainable 2.0 6.0% 4.0% 1.0 2.0% 0.0 0.0% 2010 2011 2012 2013 EBIT EBIT Margin 6
Slide 8: Annual dividend increased to 3.0 cents per share
9.00 8.00 7.00 Annual dividend increased to 3.0 6.00 cents per share $A Cents 5.00 Shares on issue (fully diluted): per share 4.00 2013 2012 3.00 56,250,650 56,474,638 2 00 2.00 1.00 0.00 0 00 2010 2011 2012 2013 EPS (diluted) DPS 7
Slide 9: Equity A$m and ROE
18 0 18.0 35 0% 35.0% 16.0 30.0% 14.0 25.0% 12.0 Equity ROE 10.0 20.0% A$m 8.0 15.0% 6.0 10.0% 4.0 5.0% 2.0 0.0 0.0% 2010 2011 2012 2013 Equity ROE 8
Slide 10: Cash Flow and Foreign Exchange
Cashflow Foreign Exchange Cash Flow (A$ m) 2013 2012 2013 sales revenue at 2012 Receipts from customers 38.86 32.74 exchange rates would have been Payments to suppliers and employees (33.54) (31.12) Gross operating cash flow 5.32 1.62 $34 08m ie 7.4% $34.08m 7 4% gain from the EBITDA 5.62 2.93 AUD
Slide 11: Balance Sheet (A$ m)
Balance Sheet (A$ m) Dec 13 Dec-13 Dec 12 Dec-12 Current assets 20.49 15.58 Group remains debt-free, with cash balance of $ $9.0m ((2012: N Non-current t assets t 1 52 1.52 1 23 1.23 $5.0m) Total assets 22.01 16.81 Cash and cash equivalents Current liabilities (5.68) (5.42) make k up 55.3% 3% of
Slide 12: Final dividend declared of 2.0 cents per share
Final dividend# declared of 2.0 cents per share (unfranked) for year ending 31 December 2013. Total interim and final dividend for 2013 Financial Year is 3.0 cents per share*, representing approximately 35 share 35.6% 6% of net profit profit, consistent with the Group’s stated policy of approxim
Slide 13: The Group
The Group Group’ss premises in Malaysia is spread across 3 locations and are seeking to acquire premises to allow consolidation into one location. New premises will also provide for a packing facility, laboratory and the Vita Health Science Knowledge Centre for staff and customer training. Acq
Slide 14: The Group now has 400 staff throughout Asia/Pacific
The Group now has 400 staff located throughout Asia/Pacific. Spirits were high when the Malaysian and Singaporean sales teams attended the 2014 “Educate 2 Succeed” kick-off meeting in January 2014. VitaHealth conducted a charity event for the National Cancer Society of Malaysia – “Health is more tha
Slide 15: 2014 forecast
The competitive landscape prevailing in Australia Australia, the political situation in Thailand and regulatory changes in China give cause for Directors to approach 2014 cautiously. Accordingly, Directors forecast: full year sales growth of approximately 13 - 15% against that reported to Dec 2013
Slide 16: Australia Revenue A$'m
Revenue‐A$'m Revenue A$ m 16.00 14.00 2013 increase 4.7% 4 7% (2012: 20 20.1%) 1%) 12.00 Lower sales growth due to tightening 10.00 of customers credit and other trading g 8.00 terms 6.00 Strong customer relationships but 4.00 operating ti ini a very competitive, titi mature market 2.00 ‐ 2010
Slide 17: Malaysia OTC Revenue A$'m
Revenue‐A$'m 12.00 2013 increase: 25.1% (2012: 18.5%) 10.00 2013 increase of 19.1% when measured in Malaysian Ringgit 8.00 Strong customer relationships, 6.00 l loyalty lt and dbbrand d awareness d driving i i sales 4.00 Competitive expanding market 2.00 Vita Health premium product positio
Slide 18: Singapore Revenue A$'m
Revenue‐A$'m 6.00 2013 increase: 27.5% (2012: 14.0%) 2013 sales increase of 19.2% when 5.00 measured in Singapore Dollars 4.00 Increased sales due to reorganisation of marketing/sales 3.00 team in 2012 2.00 Competitive moderately expanding market 1.00 Vita Health premium product ‐ position
Slide 19: New Business Units Revenue A$'m
Revenue‐A$'m Revenue A$ m 6.00 2013 increase: 32.8% (2012: 27.0%) China’s sales (RMB) increased by 5 00 5.00 37 3% (2012: 39 37.3% 39.7%) 7%) 4.00 Malaysia MLM sales (MYR) increased byy 3.8% % ((2012: 16.1% % decrease)) 3.00 Thailand sales (THB) increased by 7.3% (2012: 65.6%), impacted by p
Slide 20: Contact Details
Contact Details Telephone: p +61 3 9828 0500 Website: www.vitalifesciences.com.au Email: [email protected] Head Office: Suite 650, 1 Queens Road, Melbourne, VIC 3004 19
Slide 21: This document has been prepared by Vita Life Sciences Limited (Vita Life) and comprises
This document has been prepared by Vita Life Sciences Limited (Vita Life) and comprises written material/slides for a presentation concerning Vita Life. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dis